Brexafemme Kit (Ibrexafungerp) is temporarily unavailable in 2026. Learn why it's hard to find, what's happening with the GSK transfer, and what you can do.
You finally found a treatment that works for your recurrent vaginal yeast infections — and now you can't find it anywhere. If your pharmacy has told you Brexafemme Kit (Ibrexafungerp) is unavailable, back-ordered, or simply "not in stock," you're not imagining things. As of early 2026, Brexafemme Kit is one of the hardest prescription medications to find in the United States.
In this article, we'll explain exactly what Brexafemme Kit is, why it's so difficult to locate right now, and what steps you can take to manage your condition while availability is limited.
Brexafemme Kit contains Ibrexafungerp, a first-in-class triterpenoid antifungal medication. It was approved by the FDA in June 2021 for treating acute vulvovaginal candidiasis (vaginal yeast infections) and received a second approval in November 2022 for reducing the frequency of recurrent vulvovaginal candidiasis (RVVC).
What makes Brexafemme Kit unique is its mechanism of action. Unlike Fluconazole (Diflucan) and other azole antifungals, Brexafemme Kit works by inhibiting an enzyme called β-1,3-D-glucan synthase, which fungi need to build their cell walls. This makes it effective even against some yeast strains that are resistant to traditional antifungal medications.
For a deeper dive into how this medication works, see our guide: How Does Brexafemme Kit Work? Mechanism of Action Explained.
There are several interconnected reasons why Brexafemme Kit has been difficult — and in many cases impossible — to find:
According to the American Society of Health-System Pharmacists (ASHP), Scynexis — the company that originally developed Brexafemme — has the medication listed as temporarily unavailable with no estimated return date. This means pharmacies simply cannot order new stock from the manufacturer.
The FDA placed a clinical hold on Ibrexafungerp studies, which contributed to significant disruptions in the drug's commercial availability. While the FDA lifted this clinical hold in May 2025, the commercial supply chain has not yet recovered.
In November 2025, Scynexis completed the transfer of the Brexafemme New Drug Application (NDA) to GSK, the pharmaceutical giant that holds the commercialization license. This transfer is intended to facilitate the drug's eventual return to market, but the transition process takes time. GSK has not yet announced a specific date for when Brexafemme Kit will be available again.
There is currently no generic version of Brexafemme (Ibrexafungerp) approved by the FDA. This means there is no alternative manufacturer that can step in to fill the supply gap — patients are entirely dependent on a single source.
While the situation is frustrating, there are several practical steps you can take:
Medfinder helps you search for pharmacies that may have Brexafemme Kit in stock. While availability is extremely limited right now, checking regularly may help you locate any remaining inventory. Learn more in our guide: How to Find Brexafemme Kit in Stock Near You.
If you can't find Brexafemme Kit, your healthcare provider can help you explore other treatment options. For acute vaginal yeast infections, Fluconazole (Diflucan) remains the most widely available and affordable oral option, typically costing just $3–$15 for a single dose. Over-the-counter options like Miconazole (Monistat) and Clotrimazole are also effective for many patients.
For recurrent yeast infections, Oteseconazole (Vivjoa) is another prescription option specifically approved for RVVC prevention. Read our full breakdown: Alternatives to Brexafemme Kit If You Can't Fill Your Prescription.
Your pharmacist may be able to reach out to GSK or Scynexis directly to get the latest information on expected availability and potentially secure a supply for you as soon as the drug returns to market.
Bookmark the Brexafemme Kit Shortage Update page to stay current on the latest developments regarding availability.
Brexafemme Kit represented a genuine breakthrough for people dealing with vaginal yeast infections — especially recurrent infections that don't respond well to Fluconazole. The current unavailability is a real setback for patients who depend on it.
The good news is that the NDA transfer to GSK is complete, the FDA clinical hold has been lifted, and there are active steps being taken to bring the medication back. In the meantime, work closely with your healthcare provider to find the best alternative treatment plan for your situation.
If you're looking for help finding Brexafemme Kit or an alternative, Medfinder can help you search for availability at pharmacies near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
